Patent intelligence · US
US 10660904
Optimizing mifepristone levels for cushing's patients
Optimizing mifepristone levels for cushing's patients
Patent details — US 10660904
- Jurisdiction
- US
- Status
- granted
- Grant date
- May 26, 2020
- Expiration
- May 21, 2040
- Applicant
- Corcept Therapeutics Incorporated
- Claims
- 20
- CPC classes
- A61K, A61K31/122, A61K31/135, A61K31/136
Quick answer
US 10660904 (Optimizing mifepristone levels for cushing's patients) is held by Corcept Therapeutics Incorporated. Status: granted. Granted May 26, 2020. Expires May 21, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- Corcept Therapeutics Incorporated
- Grant date
- Expiration
- Claims
- 20
- CPC classes
- A61K, A61K31/122, A61K31/135, A61K31/136, A61K31/567
More from Corcept Therapeutics Incorporated
Related pharmaceutical patents in our USPTO index.
-
US 12370175
Glucocorticoid receptor modulators to treat pancreatic cancer
granted -
US 12370188
Formulations of dazucorilant, a glucocorticoid receptor modulator
granted -
US 12336985
Methods for shrinking pituitary tumors
granted -
US 12290551
Methods for imaging and treatment of somatostatin-receptor positive tumors
granted -
US 12285425
Glucocorticoid receptor modulators to treat cervical cancer
granted -
US 12263169
Methods of treating neuroepithelial tumors using selective glucocorticoid receptor modulators
granted -
US 12226417
Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
granted -
US 12226412
Heteroaryl-ketone fused azadecalin glucocorticoid receptor modulators
granted
Related coverage
Frequently asked questions
What is US patent 10660904?
US 10660904 (Optimizing mifepristone levels for cushing's patients) is held by Corcept Therapeutics Incorporated. Status: granted. Granted May 26, 2020. Expires May 21, 2040 (14 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 10660904?
Corcept Therapeutics Incorporated is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 120 pharmaceutical patents for this assignee.
When does US 10660904 expire?
Our index shows an expiration date of May 21, 2040 (14 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.